

<p>Informazione Regolamentata n. 20106-33-2023</p>	<p>Data/Ora Inizio Diffusione 17 Luglio 2023 18:11:21</p>	<p>Euronext Star Milan</p>
--	---	----------------------------

Societa' : PHARMANUTRA

Identificativo : 179335

Informazione  
Regolamentata

Nome utilizzatore : PHARMANUTRAN02 - Sarti Francesco

Tipologia : REGEM

Data/Ora Ricezione : 17 Luglio 2023 18:11:07

Data/Ora Inizio  
Diffusione : 17 Luglio 2023 18:11:21

Oggetto : PR PHARMANUTRA - PHN - THE BOARD  
OF DIRECTOR APPROVES THE 2022  
SUSTAINABILITY REPORT

<i>Testo del comunicato</i>
-----------------------------

Vedi allegato.

## PHARMANUTRA S.P.A.

### THE BOARD OF DIRECTORS APPROVES THE 2022 SUSTAINABILITY REPORT AND APPOINTS THE SUSTAINABILITY GOVERNANCE

**The second edition of the report also presents the sustainability plan with concrete actions and projects to take the Group towards a fair as well as sustainable future, continuing to generate value for investors and all stakeholders**

*Pisa, 17 July 2023 - [PharmaNutra S.p.A.](#)'s Board of Directors (MTA; Ticker PHN), a company specialising in mineral-based nutritional supplements and medical devices for muscles and joints, has approved today the 2022 Sustainability Report. Furthermore, it has appointed the sustainability governance.*

**Andrea Lacorte, Chairman of PharmaNutra S.p.A., stated:** "PharmaNutra Group has a strong focus and a constant commitment to sustainability. People are very important to us and that is why we put their safety first, promoting programmes to further improve standards relating to protection and prevention. In our strategic sustainability plan, we are certain that building a peaceful and inclusive work environment is of paramount importance. Such an environment must allow people to fulfil their potential so that they can be valued as well as rewarded according to their commitment and talent. It is precisely with these aims in mind that the Group's new headquarters was designed, which will finally be operational starting from next September, with a strong focus on reducing the impact on the climate. To this end, we will purchase green energy quotas from the grid, use electrical power from renewable sources, and strive to use the natural resources as well as raw materials we need in a circular manner. Such a commitment to a fairer and more sustainable future also extends to the social sphere. In fact, we plan to intensify our relations with educational institutions, continuing to promote actions to support the communities in which we operate, but not only. Our strategy envisages the increasingly active and responsible involvement of all those in the supply chain, engaging them in a process of evaluation and performance improvement related to environmental, social and business ethics issues, with a focus on the respect for human rights". The 2022 Sustainability Report has been prepared on a voluntary basis, as PharmaNutra S.p.A. is exempt from the mandatory reporting of the Non-Financial Statement according to the Italian Legislative Decree no. 254/2016 currently in force, is subject to a limited audit by KPMG S.p.A. and has been prepared in accordance with the Global Reporting Initiative (GRI), which is currently the most recognised and widespread non-financial reporting standard at international level.

In the second PharmaNutra Group Sustainability Report, in addition to representing the progress made and the objectives achieved, the medium-term sustainability strategy (the Sustainability Plan) is presented for the first time. It is a concrete plan, made up of actions and projects, which aims to lead the Group towards a fair and sustainable future, while continuing to generate value for investors, customers and all stakeholders. The Sustainability Plan is divided into six high-level areas of commitment:

- **Governance:** oriented towards sustainable success
- **People:** generating ESG involvement, awareness and ownership
- **Environment:** ensuring efficient consumption management and reducing environmental impacts
- **Community:** contributing to the well-being and improvement of the quality of life of the local community
- **Value chain:** ESG-oriented strengthening of the supply chain
- **Innovation:** ensuring the protection of intellectual property, patents and raw materials.

For each area, operational objectives have been identified to be pursued with estimated deadlines for completion.

A dedicated governance structure was appointed to pursue the objectives outlined in the Sustainability Plan aimed at a "sustainable success" in accordance with the Corporate Governance Code for companies listed on the MTA market, as follows:

- assignment of specific proxies in the ESG area to the Executive Director Mr Germano Tarantino;
- assignment to the Control and Risk Committee, which becomes the Control, Risk and Sustainability Committee, of the task to propose and advise the Board of Directors on sustainability issues;
- appointment of the ESG manager and definition of the composition of the operational team to implement the operational actions foreseen in the plan and the reporting of results, contributing to the dissemination of the sustainability culture.

The Group's 2022 Sustainability Report will be available in the *Sustainability* section of the website [PharmaNutra.it](https://www.pharmanutra.it).

#### PharmaNutra S.p.A.

*Founded and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra is a company established in 2003 that develops unique nutritional supplements and innovative medical devices, taking care of the entire production*

process, from proprietary raw materials to the finished product. PharmaNutra is a leader in the production of iron-based nutritional supplements under the SiderAL® brand, where it holds important patents on Sucrosomal® Technology, and is considered one of the emerging top players in the medical device sector dedicated to restoring joint capacity thanks to the Cetilar® brand. The effectiveness of the products is demonstrated by a number of scientific evidences, including more than 120 publications. In Italy, the sales activity is carried out through a network of over 160 Commercial Scientific Informants serving the medical class and dedicated to the exclusive marketing of products to pharmacies and parapharmacies throughout the national territory. Sales abroad are guaranteed in over 71 countries through 45 partners selected among the leading pharmaceutical companies. Over the years, the Group has developed a precise strategy in the management and production of intellectual property, based on the integrated management of all components: proprietary raw materials, patents, trademarks and clinical evidence.

[PharmaNutra.it](http://PharmaNutra.it)

For further details:

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b - 56122 Pisa, Italy

Tel. +39 050 7846500

[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

Internal Press Office

[press@calabughi.com](mailto:press@calabughi.com)

**Press Office - Spriano Communication & Partners**

Via Santa Radegonda, 16 - 20121 Milan, Italy

Tel. +39 02 83635708

Matteo Russo

[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)

Cristina Tronconi

[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

Fine Comunicato n.20106-33

Numero di Pagine: 5